MDS Nordion (ticker: MDS.TO, exchange: Toronto Stock Exchange (.TO)) News Release - 3/3/2005


MDS Pharma Services to Host Grand Opening of Expanded Singapore Facility

MONTREAL--(BUSINESS WIRE)--March 3, 2005--MDS Pharma Services (NYSE:MDZ)(TSX:MDS), a leading provider of innovative drug discovery and development solutions, will host a grand opening event for its newly expanded Singapore facility. This expansion houses MDS Pharma Services' growing presence in Singapore, which currently includes central lab and ECG study coordination services, logistics and global clinical development services. Keynote speaker for the grand opening program will be Andy Lee, Senior Director, Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, who will discuss "The Global Nature of Clinical Trials: Emergence of Asia as a Key Player."


       WHAT: Grand opening ceremony for MDS Pharma Services' expanded
             Singapore facility including ribbon-cutting ceremony,
             lab tours, gala dinner and keynote speaker

       WHEN: Monday, April 11, 2005
             Press Conference at 2:30 PM

      WHERE: 2 International Business Park
             #10-06, Tower 1, The Strategy
             Singapore 609930

Individuals interested in attending this grand opening event are encouraged to view the complete agenda online at www.mdsps.com/events/singapore2005.htm. Registration is available on that Web page or via e-mail at Singapore.launch@mdsps.com.

MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process - early stage: lead optimization, pre-IND research, pharmaceutical and biopharmaceutical development, early clinical research (bioequivalence, phases I-IIa) and bioanalysis; and late stage: global clinical development (phases IIb-IV) and central lab. For more information, visit MDS Pharma Services' Web site at www.mdsps.com.

MDS Pharma Services is an integral part of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. has more than 9,000 highly skilled people in 25 countries providing a diverse range of superior products and services to increase our customers' speed, precision and productivity in the drug development and disease diagnosis processes. We are a global health and life sciences company, recognized for our reliability and collaborative relationships. Please refer to our website at www.mdsintl.com to find out more about how we help create better outcomes in the treatment of disease.

For further information regarding the event, please contact Raymond Yeung, MDS Pharma Services, 2 International Business Park, #10-06, Tower 1, The Strategy, Singapore 609930, Tel: +65-6896-5301.


    CONTACT: MDS Pharma Services
             For Media Inquiries:
             Kim Peacock
             (402) 476-2811
             621 Rose Street, Lincoln Neb.
             www.mdsps.com

    SOURCE: MDS Pharma Services
Legal Notice